Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J0878
1 MG
Medicare payment limit per unit (Q4 2026): $0.027
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 1000 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | CMS Policy |
| Facility outpatient hospital services | 1000 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | CMS Policy |
| DME supplier services | 1000 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$0.027per 1 MG
Effective Oct 1, 2026 – Dec 31, 2026 · AMP-based payment limit (per CMS note) · based on Q2 2026 ASP data · coinsurance 20.000%
CMS note: “AMP-based payment limit”
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.027 | 1 MG | 20% | −6.9% | AMP-based payment limit |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.029 | 1 MG | 20% | −14.7% |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 16729-0434-05 | DaptomycinAccord Healthcare Inc | 1 × 1 | 350 | 350 | $9.45 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 16729-0434-45 | DaptomycinAccord Healthcare Inc | 1 × 10 | 350 | 3,500 | $94.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 16729-0435-05 | DaptomycinAccord Healthcare Inc | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 60505-6229-04 | DaptomycinApotex Corp | 1 × 1 | 500 | 500 | $13.50 | ASP | Q4 2022 – Q4 2026 | ListedDaptomycin |
| 71839-0107-01 | DaptomycinBE Pharmaceuticals Inc. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 71839-0108-01 | DaptomycinBE Pharmaceuticals Inc. | 1 × 1 | 350 | 350 | $9.45 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 70377-0093-91 | DaptomycinBiocon Pharma Inc | 1 × 1 | 500 | 500 | $13.50 | ASP | Q2 2025 – Q4 2026 | ListedDaptomycin |
| 68001-0376-68 | DaptomycinBluePoint Laboratories | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 72572-0102-01 | DaptomycinCivica, Inc. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 43598-0413-11 | DaptomycinDr. Reddy's Laboratories Inc. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 43598-0476-11 | DaptomycinDr. Reddy's Laboratories Inc. | 1 × 1 | 350 | 350 | $9.45 | ASP | Q2 2022 – Q4 2026 | ListedDaptomycin |
| 55150-0344-01 | DaptomycinEugia US LLC | 1 × 1 | 500 | 500 | $13.50 | ASP | Q3 2022 – Q4 2026 | ListedDaptomycin |
| 00143-9378-01 | DaptomycinHikma Pharmaceuticals USA Inc. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | Excluded listingDaptomycin |
| 00143-9444-01 | DaptomycinHikma Pharmaceuticals USA Inc. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q2 2026 – Q4 2026 | ListedDaptomycin |
| 00143-9465-01 | DaptomycinHikma Pharmaceuticals USA Inc. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2026 – Q4 2026 | ListedDaptomycin |
| 71288-0016-15 | DaptomycinMeitheal Pharmaceuticals Inc. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q3 2023 – Q4 2026 | ListedDaptomycin |
| 71288-0016-91 | DaptomycinMeitheal Pharmaceuticals Inc. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q3 2023 – Q4 2026 | ListedDaptomycin |
| 71288-0016-95 | DaptomycinMeitheal Pharmaceuticals Inc. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q3 2023 – Q4 2026 | ListedDaptomycin |
| 71288-0017-15 | DaptomycinMeitheal Pharmaceuticals Inc. | 1 × 1 | 350 | 350 | $9.45 | ASP | Q3 2023 – Q4 2026 | ListedDaptomycin |
| 71288-0017-91 | DaptomycinMeitheal Pharmaceuticals Inc. | 1 × 1 | 350 | 350 | $9.45 | ASP | Q3 2023 – Q4 2026 | ListedDaptomycin |
| 67457-0813-50 | DaptomycinMylan Institutional LLC | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 67457-0941-15 | DaptomycinMylan Institutional LLC | 1 × 1 | 500 | 500 | $13.50 | ASP | Q2 2024 – Q4 2026 | ListedDaptomycin |
| 16714-0892-01 | DaptomycinNorthstar RxLLC | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | Excluded listingDaptomycin |
| 72603-0147-01 | DaptomycinNorthstar RxLLC | 1 × 1 | 350 | 350 | $9.45 | ASP | Q1 2026 – Q4 2026 | ListedDaptomycin |
| 72603-0152-01 | DaptomycinNorthstar RxLLC | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2026 – Q4 2026 | ListedDaptomycin |
| 25021-0174-15 | DaptomycinSagent Pharmaceuticals | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 25021-0174-16 | DaptomycinSagent Pharmaceuticals | 1 × 10 | 500 | 5,000 | $135.00 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 25021-0179-15 | DaptomycinSagent Pharmaceuticals | 1 × 1 | 350 | 350 | $9.45 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 25021-0179-16 | DaptomycinSagent Pharmaceuticals | 1 × 10 | 350 | 3,500 | $94.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 25021-0179-66 | DaptomycinSagent Pharmaceuticals | 1 × 1 | 350 | 350 | $9.45 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 25021-0179-67 | DaptomycinSagent Pharmaceuticals | 1 × 10 | 350 | 3,500 | $94.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 70594-0034-01 | DaptomycinXellia Pharmaceuticals USA, LLC. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2021 – Q4 2026 | ListedDaptomycin |
| 70594-0034-02 | DaptomycinXellia Pharmaceuticals USA, LLC. | 1 × 1 | 500 | 500 | $13.50 | ASP | Q1 2022 – Q4 2026 | ListedDaptomycin |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 69097-0807-37 | DaptomycinCIPLA USA INC. | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2024 | Dates changed | P — Payment change | Added Jan 1, 2005 · action effective Jan 1, 2024 · termination — |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2005 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| CMS Policy |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| AMP-based payment limit |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.034 | 1 MG | 20% | +21.4% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $0.028 | 1 MG | 20% | +0.0% | AMP-based payment limit |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $0.028 | 1 MG | 20% | −6.7% | AMP-based payment limit |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $0.030 | 1 MG | 20% | −9.1% | AMP-based payment limit |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $0.033 | 1 MG | 20% | −5.7% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $0.035 | 1 MG | 20% | +9.4% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $0.032 | 1 MG | 20% | +45.5% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $0.022 | 1 MG | 20% | −78.8% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $0.104 | 1 MG | 20% | +173.7% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $0.038 | 1 MG | 20% | −5.0% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $0.040 | 1 MG | 20% | −48.7% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $0.078 | 1 MG | 20% | +90.2% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $0.041 | 1 MG | 20% | −14.6% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $0.048 | 1 MG | — | +9.1% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $0.044 | 1 MG | — | −6.4% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $0.047 | 1 MG | — | −7.8% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $0.051 | 1 MG | — | −5.6% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $0.054 | 1 MG | — | −5.3% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $0.057 | 1 MG | — | −28.7% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $0.080 | 1 MG | — | −14.9% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $0.094 | 1 MG | — | −26.0% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $0.127 | 1 MG | — | — | — |
|---|
| 69097-0850-67 | DaptomycinCIPLA USA INC. | 1 × 1 | 350 | 350 | ASP | Q3 2021 – Q4 2024Not in Q4 2026 file | Excluded listingDaptomycin |
|---|
| 72572-0100-01 | DaptomycinCivica, Inc. | 1 × 1 | 350 | 350 | ASP | Q1 2021 – Q3 2024Not in Q4 2026 file | ListedDaptomycin |
|---|
| 67919-0011-01 | CubicinCUBIST PHARMACEUTICALS | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingCubicin |
|---|
| 67919-0012-02 | CubicinCUBIST PHARMACEUTICALS | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingCubicin Rf |
|---|
| 63323-0585-15 | DaptomycinFRESENIUS KABI | 1 × 1 | 350 | 350 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingDaptomycin |
|---|
| 63323-0371-10 | DaptomycinFreseniUS Kabi USA, LLC | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q1 2026Not in Q4 2026 file | ListedDaptomycin |
|---|
| 63323-0371-19 | DaptomycinFreseniUS Kabi USA, LLC | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q1 2026Not in Q4 2026 file | ListedDaptomycin |
|---|
| 63323-0871-15 | DaptomycinFreseniUS Kabi USA, LLC | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | Excluded listingDaptomycin |
|---|
| 67919-0012-01 | CubicinMerck Sharp & Dohme LLC | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | Not found |
|---|
| 00409-0106-01 | DaptomycinPFIZER INC. | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingDaptomycin |
|---|
| 00409-0120-01 | DaptomycinPFIZER INC. | 1 × 1 | 350 | 350 | ASP | Q1 2022 – Q4 2022Not in Q4 2026 file | ListedDaptomycin |
|---|
| 00409-0122-01 | DaptomycinPFIZER INC. | 1 × 1 | 500 | 500 | ASP | Q1 2022 – Q4 2022Not in Q4 2026 file | ListedDaptomycin |
|---|
| 00409-2757-01 | DaptomycinPFIZER INC. | 1 × 1 | 500 | 500 | ASP | Q2 2021 – Q4 2024Not in Q4 2026 file | Excluded listingDaptomycin |
|---|
| 00409-5933-01 | DaptomycinPFIZER INC. | 1 × 1 | 350 | 350 | ASP | Q2 2021 – Q4 2022Not in Q4 2026 file | Excluded listingDaptomycin |
|---|
| 00781-3295-70 | DaptomycinSANDOZ | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingDaptomycin |
|---|
| 00703-0125-01 | DaptomycinSICOR PHARMACEUTICALS, INC. | 1 × 1 | 500 | 500 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingDaptomycin |
|---|
| 70594-0053-01 | DaptomycinXELLIA PHARMACEUTICALS USA, LLC | 1 × 1 | 350 | 350 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | ListedDaptomycin |
|---|